You are here

  • Home
  • Archive
  • Volume 72, Issue 1
  • Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial

Article Text

Article menu
Download PDFPDF
Letters
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial

https://doi.org/10.1136/annrheumdis-2012-202071

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding Supported by Roche, Woerden, The Netherlands.

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval The ethics committee of the University Medical Center Groningen (METC approval: 05.229).

    • Provenance and peer review Not commissioned; externally peer reviewed.